Literature DB >> 22906936

CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma.

Jian Y Cheng1, Ratnavelu Kananathan.   

Abstract

This case report documents the use of the CIMAvax Epidermal Growth Factor vaccine regimen in a 54 y old female with stage IIIb non-small cell lung carcinoma. Even after 48 mo since diagnosis her ECOG performance remains at zero. Further, this report documents a reaction to the vaccine of grade 3 severity not previously documented.

Entities:  

Keywords:  cimavax; epidermal growth factor (EGF); lung; non small cell lung cancer (NSCLC)

Mesh：

Substances：

Year:  2012        PMID： 22906936      PMCID： PMC3656068          DOI： 10.4161/hv.21744

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  21 in total

1.  Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers.

Authors:  A Pérez; F Dickinson; Z Cinza; A Ruíz; T Serrano; J Sosa; S González; Y Gutiérrez; C Nazábal; O Gutiérrez; D Guzmán; M Díaz; M Delgado; E Caballero; G Sardiñas; A Alvarez; A Martín; G Guillén; R Silva
Journal:  Biotechnol Appl Biochem       Date:  2001-10       Impact factor: 2.431

Review 2.  Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.

Authors:  Cheryl Lai-Lai Chiang; Lana E Kandalaft; George Coukos
Journal:  Int Rev Immunol       Date:  2011 Apr-Jun       Impact factor: 5.311

3.  Chemotherapy for metastatic non-small-cell lung cancer--can that dog hunt?

Authors:  D H Johnson
Journal:  J Natl Cancer Inst       Date:  1993-05-19       Impact factor: 13.506

4.  A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.

Authors:  H Toledo; A Baly; O Castro; S Resik; J Laferté; F Rolo; L Navea; L Lobaina; O Cruz; J Míguez; T Serrano; B Sierra; L Pérez; M E Ricardo; M Dubed; A L Lubián; M Blanco; J C Millán; A Ortega; E Iglesias; E Pentón; Z Martín; J Pérez; M Díaz; C A Duarte
Journal:  Vaccine       Date:  2001-07-20       Impact factor: 3.641

5.  Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial.

Authors:  Tania Crombet Ramos; Elia Neninger Vinageras; Mauricio Catalá Ferrer; Beatriz García Verdecia; Idrissa Leonard Rupalé; Liana Martínez Pérez; Gisela González Marinello; Rolando Pérez Rodríguez; Agustín Lage Dávila
Journal:  Cancer Biol Ther       Date:  2006-02-15       Impact factor: 4.742

6.  Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.

Authors:  G Gonzalez; T Crombet; F Torres; M Catala; L Alfonso; M Osorio; E Neninger; B Garcia; A Mulet; R Perez; R Lage
Journal:  Ann Oncol       Date:  2003-03       Impact factor: 32.976

Review 7.  Autoimmunization to epidermal growth factor, a component of the immunological homunculus.

Authors:  G Gonzalez; E Montero; K Leon; I R Cohen; A Lage
Journal:  Autoimmun Rev       Date:  2002-02       Impact factor: 9.754

8.  Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.

Authors:  Barney S Graham; M Juliana McElrath; Michael C Keefer; Kyle Rybczyk; David Berger; Kent J Weinhold; Janet Ottinger; Guido Ferarri; David C Montefiori; Don Stablein; Carol Smith; Richard Ginsberg; John Eldridge; Ann Duerr; Pat Fast; Barton F Haynes
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

9.  A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.

Authors:  G González; T Crombet; M Catalá; V Mirabal; J C Hernández; Y González; P Marinello; G Guillén; A Lage
Journal:  Ann Oncol       Date:  1998-04       Impact factor: 32.976

Review 10.  Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.

Authors:  H-W Lo; M-C Hung
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640
View more
  1 in total

Review 1.  Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael W DeGregorio
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.